TITLE

Trasylol marketing suspended

PUB. DATE
January 2008
SOURCE
Drug Formulary Review;Jan2008, Vol. 24 Issue 1, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has asked Bayer Pharmaceuticals Corp. for the suspension of the marketing of Trasylol®, a drug for controlling bleeding during heart surgery. The FDA claims that its move is in line with the interest of public safety since preliminary results from a Canadian study suggests that Trasylol® may contribute to an increased risk of death. FDA also announced that it was working Bayer for the phaseout of the drug in order to prevent shortages of other drugs used for that purpose.
ACCESSION #
28161519

 

Related Articles

  • FDA advises caution for Trasylol.  // Reactions Weekly;10/7/2006, Issue 1122, p3 

    The article reports on the advisory given by the U.S. Food and Drug Administration for healthcare providers to warrant caution in the use of Trasylol in response to a study by Bayer Pharmaceuticals which shows that the drug may increase the risk for serious kidney damage, congestive heart...

  • Hemostatic agent suspended from market.  // Pharmacy Today;Dec2007, Vol. 13 Issue 12, p1 

    The article reports on the agreement between the U.S. Food and Drug Administration and Bayer Pharmaceuticals Corp. to suspend the marketing of aprotinin. This is due to preliminary findings indicating an increased risk of death associated with its use. Aprotinin is a drug used to reduce the...

  • U.S. FOOD & DRUG ADMINISTRATIONS UPDATE.  // Materials Management in Health Care;Jan2008, Vol. 17 Issue 1, p7 

    The article offers news briefs related to actions of the U.S. Food and Drug Administration (FDA). Bayer Pharmaceuticals agreed to a temporary marketing suspension of Trasylol, an antifibrinolytic drug used to control bleeding during heart surgery. Abbott Laboratories Inc.'s Xience Everolimus...

  • Aprotinin injection labeling revised.  // Drug Formulary Review;Feb2007, Vol. 23 Issue 2, p15 

    The article reports on the move of the U.S. Food and Drug Administration to approve revised labeling for the aprotinin injection Trasylol from Bayer. The revision strengthens the safety warnings and limits its approved usage to specific situations. The injection is given to patients before heart...

  • FDA Warnings Dominate Pharmaceutical News.  // Infectious Disease Alert;Jan2008, Vol. 27 Issue 4, p1 

    The article presents updates on issues related to the U.S. Food and Drug Administration (FDA). Bayer Pharmaceuticals is conforming with the request of the FDA to suspend the marketing of aprotonin. Several new generics such as oxcarbazepines, hydrocodone/ibuprofen and rivastigmine has been...

  • NEW FORMULATIONS.  // Drug Topics;10/6/2003, Vol. 147 Issue 19, p115 

    Reports on new drug formulations approved by the U.S. Food and Drug Administration as of October 2003. Cipro XR 1000 milligrams, developed by Bayer Pharmaceuticals Corp., indicated for treatment of complicated urinary tract infections and acyte uncomplicated pyelonephritis; Wellbutrin XL from...

  • Treatment for Advanced Kidney Cancer.  // FDA Consumer;Mar/Apr2006, Vol. 40 Issue 2, p3 

    The article reports on the approval by the U.S. Food and Drug Administration on Nexavar, an anti-cancer drug used to treat adults with advanced renal cell carcinoma. According to Steven Galson, director of the Center for Drug Evaluation and Research at FDA, the approval of Nexavar in December...

  • NEW FORMULATIONS.  // Drug Topics;1/9/2006, Vol. 150 Issue 1, p51 

    The article reports on the new formulations in the pharmaceutical products approved by the Food and Drug Administration in the U.S. A higher-strength, non-calcium phosphate binder for Fosrenol has been approved to achieve better target phosphate levels in adult patients who have...

  • Product Preview.  // Urology Times;Jan2004, Vol. 32 Issue 1, p24 

    Presents various updates on urological drugs and devices. GlaxoSmithKline clinical trial on drug to treat benign prostatic hyperplasia in men; Extension of marketing exclusivity granted by the U.S. Food and Drug Administration to Bayer Pharmaceuticals for its fluoroquinolone antibiotic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics